Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 study of MK-7684A with or without docetaxel versus docetaxel in previously treated metastatic non-small cell lung cancer
2020-004034-38Phase 2Active
- Sponsor
- Merck & Co.
- Start
- Feb 2021
- Modality
- Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in non-small cell lung cancer (NSCLC) comparing MK-7684A + docetaxel, MK-7684A monotherapy and Placebo + docetaxel (3 arms). Primary endpoint: Progression-free survival. Started Feb 2021; status: active.
02
Drugs
vibostolimab + pembrolizumabdocetaxel
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on 2020-004034-38.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2020-004034-38.